-transparent.png){kind=logo}
The pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 has been studied in 6 healthy male volunteers following a single intravenous dose of 2.5 mg. The drug was only slightly bound to plasma proteins (40 +/- 8%, mean +/- SD). A negligible amount (less than 0.2% of the dose) of unchanged drug was recovered in urine. Hepatic elimination was rapid, as shown by a short t1/2 of 0.9 +/- 0.2 h, and high total plasma and blood clearances of 691 +/- 216 ml/min and 716 +/- 199 ml/min, respectively. The fast decline of plasma levels from about 60 to 2 ng/ml accounts for the short-lasting reversal of benzodiazepine-induced sedation by Ro 15-1788.
Related Publications
U Klotz, and
G Ziegler, and
I W Reimann
January 1987,
Journal de toxicologie clinique et experimentale,
U Klotz, and
G Ziegler, and
I W Reimann
October 1986,
British journal of clinical pharmacology,
U Klotz, and
G Ziegler, and
I W Reimann
June 1986,
Archives of internal medicine,
U Klotz, and
G Ziegler, and
I W Reimann
July 1981,
Lancet (London, England),
U Klotz, and
G Ziegler, and
I W Reimann
January 1983,
Psychopharmacology,
U Klotz, and
G Ziegler, and
I W Reimann
August 1984,
Der Anaesthesist,
U Klotz, and
G Ziegler, and
I W Reimann
May 1984,
Pharmacopsychiatry,
U Klotz, and
G Ziegler, and
I W Reimann
July 1988,
Der Anaesthesist,
U Klotz, and
G Ziegler, and
I W Reimann
January 1986,
Psychopharmacology,
U Klotz, and
G Ziegler, and
I W Reimann
January 1982,
Psychopharmacology,
